From: Updates on clinical studies of selenium supplementation in radiotherapy
Study no. | Reference | Site of research | Number of patients | Study design | Type of cancer/disease | Radiotherapy delivery method |
---|---|---|---|---|---|---|
1 | Pothier et al. [17] | USA | n = 71 | Observation of Se levels | Upper gastrointestinal cancer | Not mentioned |
2 | Antila et al. [18] | Finland | n = 24 | Observation of Se levels | Breast cancer | Energy photons followed by 6–12 MeV electrons |
3 | Piccinini et al. [19] | Italy | n = 66 | Observation of Se levels | Breast cancer (n = 38), lung cancer (n = 28) | Not mentioned |
4 | Rostkowska-Nadolska et al. [20] | Poland | n = 78 | Observation of Se levels | carcinoma of the larynx | X-Ray therapy |
5 | Yadav et al. [21] | India | n = 30 | Observation of Se levels | Head and neck cancer | Not mentioned |
6 | Last et al. [22] | UK | n = 100 | Observation of Se levels | Non-Hodgkin’s lymphoma | Not mentioned |
7 | Fraunholz et al. [23] | Germany | n = 224 | Observation of Se levels | Breast cancer (n = 94); cervical csncer (n = 25); head and neck cancer (n = 23); lung cancer (n = 19); prostate (n = 13); other (n = 50) | 6-MV and/or 25-MV photons generated by a linear accelerator |
8 | Franca et al. [24] | Brazil | n = 209 | Observation of Se levels | Breast cancer | Not mentioned |
9 | Zeng YC et al. [25] | China | n = 95 | Observation of Se levels | Non-small cell lung cancer with brain metastases | 6MV external beam radiotherapy |
10 | Eroglu C et al. [26] | Turkey | n = 47 | Observation of Se levels | Head and neck cancer | Not mentioned |
11 | Pakdaman, [27] | Germany | n = 32 | Se supplementation | Brain tumor | Not mentioned |
12 | Kiremidjian-Schumacher et al. [28] | USA | n = 33 supplemented (n = 17) placebo (n = 16) | Se supplementation | Head and neck cancer | Not mentioned |
13 | Micke et al. [29] | Germany | n = 48 | Se supplementation | Secondary lymphedema | a linear accelerator with 6-MeV photons or a 60Co treatment unit |
14 | Elango et al. [30] | India | n = 126 | Se supplementation | Oral cancer | a tele-cobalt beam (Theratron-780-60Co; phoenix-60Co; Gammatron-60Co) |
15 | Muecke et al. [31] | Germany | n = 81 supplemented (n = 39) control group (n = 42) | Se supplementation | Cervical cancer (n = 11); uterine cancer (n = 70) | 6- to 18-MV linear accelerator |
16 | Buntzel et al. [32] | Germany | n = 39 | Se supplementation | Head and neck cancer | Not mentioned |
 |  |  | Total = 1303 |  |  |  |